Comparative Study of Circulating Tumor DNA and Computerized Tomography Monitoring in Untreated Diffuse Large B-Cell Lymphoma

Background— Diffuse large-B-cell lymphoma (DLBCL) is curable but when treatment fails, outcome is poor. Imaging scans help identify patients at risk of treatment failure but are often imprecise, and the radiation exposure is a potential health risk. Specific, sensitive and readily available biomarkers of treatment failure are needed. Methods— We retrospectively analyzed cell-free circulating tumor DNA (ctDNA) in patients treated on one of 3 treatment protocols using quantitative next-generation DNA sequencing. Eligible patients had DLBCL, no evidence of indolent lymphoma and were previously untreated. Serial serum samples and concurrent computed tomography scans were obtained at specified times during most treatment cycles and 5-years of follow-up. VDJ gene segments of the rearranged immunoglobulin receptor genes were amplified and sequenced from pre-treatment specimens and serum ctDNA encoding the VDJ rearrangements was quantitated. Findings— Tumor clonotype(s) were identified in pretreatment specimens from 126 patients who were followed for a median (interquartile range) of 11 (6.8 to 14.2) years. Interim ctDNA monitoring at the end of 2 treatment cycles in 108 patients showed a time to progression (TTP) of 41.7% (95% Confidence Interval (CI): 22.2% to 60.1%) and 80.2% (95% CI: 69.6% to 87.3%), at 5-years (p<0.0001) in patients with and without detectable ctDNA, respectively, and a positive and negative predicative value (PPV and NPV) of 63% and 80%, respectively. Surveillance ctDNA monitoring was performed in 107 patients who achieved complete remission. A Cox proportional hazards model showed patients who developed detectable ctDNA during surveillance had a hazard ratio 228 times that of patients with undetectable ctDNA for clinical disease progression (95% CI: 51 to 1022) (p<0.0001). Surveillance ctDNA had a PPV and NPV of 88% and 98%, respectively, and identified recurrence a median (range) of 3.5 months (0 to 200) before evidence of clinical disease. Interpretation— Surveillance ctDNA identifies patients at risk of recurrence before clinical evidence of disease in most patients and results in lower disease burden at relapse. Interim ctDNA is a promising biomarker to identify patients at high risk of treatment failure. Kruskal-Wallis test was used. Sensitivity, specificity, and positive and negative predictive (PPV and NPV) of ctDNA detection of clinical disease were calculated based on the final determinations of ctDNA and clinical progression or not as dichotomous outcomes. 27 All p-values are two-tailed. Statistical analyses were performed using SAS version 9.3 and Prism version 6.0. illustrates following is Two patients (#35, single low-level positive ctDNA during surveillance and did not have clinical progression. samples time points were reanalyzed both and were negative ctDNA the suggesting these were false

[1]  J. Cerhan,et al.  Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Staudt,et al.  A prospective study of mediastinal gray-zone lymphoma. , 2014, Blood.

[3]  L. Staudt,et al.  DNA Sequencing-Based Monitoring Of Serum Predicts Clinical Relapse Before CT Imaging in Diffuse Large B-Cell Lymphoma , 2013 .

[4]  A. LaCasce,et al.  Detection of circulating tumour DNA in patients with aggressive B‐cell non‐Hodgkin lymphoma , 2013, British journal of haematology.

[5]  R. Hicks,et al.  Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy , 2013, British Journal of Cancer.

[6]  Elaine S. Jaffe,et al.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. , 2013, The New England journal of medicine.

[7]  D. Campana,et al.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. , 2012, Blood.

[8]  E. Jaffe,et al.  The Histological and Biological Spectrum of Diffuse Large B-Cell Lymphoma in the World Health Organization Classification , 2012, Cancer journal.

[9]  C. Smith Diagnostic tests (1) – sensitivity and specificity , 2012, Phlebology.

[10]  J. Armitage Who benefits from surveillance imaging? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Kostas Stamatopoulos,et al.  Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. , 2012, Blood.

[12]  C. Copie-Bergman,et al.  Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Andrew Homb,et al.  18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.

[14]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Wilson,et al.  The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. , 2010, Blood.

[16]  A. Zelenetz,et al.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Advani,et al.  Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. , 2010, Blood.

[18]  L. Staudt,et al.  Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[20]  D. Brenner,et al.  Computed tomography--an increasing source of radiation exposure. , 2007, The New England journal of medicine.

[21]  A. Zelenetz,et al.  Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Zelenetz,et al.  Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. , 2003, Blood.

[23]  L. Staudt,et al.  Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. , 2002, Blood.

[24]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[25]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[27]  M. A. Tanner,et al.  One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Waldmann,et al.  Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. , 1983, The New England journal of medicine.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .